Blood and Lymph Conditions

All Conditions

Neoplasms

Immune System Diseases

Symptoms and General Pathology

Heart and Blood Diseases

Rare Diseases

Thrombocytopenia

Preleukemia

Myelodysplastic Syndromes

Purpura, Thrombocytopenic, Idiopathic

Purpura

Purpura, Thrombocytopenic

Syndrome

Blood Platelet Disorders

Hematologic Diseases

Cytopenia

Hemostatic Disorders

Blood Coagulation Disorders

Thrombotic Microangiopathies

Hemorrhagic Disorders

Autoimmune Diseases

Hemorrhage

Skin Manifestations

Bone Marrow Diseases

Precancerous Conditions

Immune Thrombocytopenia

Idiopathic Thrombocytopenic Purpura

All Drugs and Chemicals

Antibodies

Antibodies, Monoclonal

Immunoglobulins

* Thrombopoietin : 7 ml whole blood.
* Anti-platelet antibodies free : 14 ml whole blood.
* Anti-platelet antibodies bound :

If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation.

Blood samples

Jean-François VIALLARD, Prof

Pierre DUFFAU, Prof

Sophie DIMICOLI-SALAZAR, MD

Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

Contribution of Anti-platelet Antibodies Identified With" Monoclonal Antibody Immobilization of Platelet Antigens" Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

Ministry for Health and Solidarity, France

University Hospital, Bordeaux

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis	NCT04800458	Thrombocytopeni... Immune Thromboc... Myelodysplasia	Blood samples	18 Years -	University Hospital, Bordeaux
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis	NCT04800458	Thrombocytopeni... Immune Thromboc... Myelodysplasia	Blood samples	18 Years -	University Hospital, Bordeaux

Spots Global Cancer Trial Database for monoclonal antibody immobilization of platelet antigens assay